Stimuliver
Giles Dudley is the Chief Business Officer at Stimuliver, a cell therapy company, and AdaptVac, a joint-venture focusing on vaccine development. Giles also serves as a Spark Program Member and Advisor at Spark Denmark, a Startup Mentor at NOME, and an Advisor at Innovate UK. Previously, Giles was the Director of Business Development at BioInnovation Institute and holds various board positions in companies focusing on CRISPR technology, therapeutics, male infertility treatment, and psychedelic drug development. Giles holds a PhD in Virology from the University of Glasgow and a B.Sc. in Molecular Biology and Biochemistry from the University of the West of England.
This person is not in any teams
Stimuliver
Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list. Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.